Dr. Salgia on Next-Generation Sequencing in Lung Cancer

Ravi Salgia, MD, PhD
Published: Tuesday, Jan 02, 2018



Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Next-generation sequencing can detect mutations, translocations, and amplifications, explains Salgia. The FDA has just approved one of the tests. It is important for the test to be in the tumor tissue, but there might not be enough tissue in the lung. If there is not enough tumor tissue, a liquid biopsy is a possible alternative, according to Salgia.
 


Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Next-generation sequencing can detect mutations, translocations, and amplifications, explains Salgia. The FDA has just approved one of the tests. It is important for the test to be in the tumor tissue, but there might not be enough tissue in the lung. If there is not enough tumor tissue, a liquid biopsy is a possible alternative, according to Salgia.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x